Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

71

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Ruihua Xu, Doctor
  • Número de telefone: 020-87343468
  • E-mail: xurh@syscc.org.cn

Locais de estudo

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100034
        • Ainda não está recrutando
        • Peking University First Hospital
        • Contato:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400016
        • Ainda não está recrutando
        • The First Affiliated Hospital of Chongqing Medical University
        • Contato:
    • Gansu
      • Lanzhou, Gansu, China, 730050
        • Ainda não está recrutando
        • Gansu Provincial Tumor Hospital
        • Contato:
    • Guangdong
      • Foshan, Guangdong, China, 528000
        • Ainda não está recrutando
        • The First People's Hospital of Foshan
        • Contato:
      • Guangzhou, Guangdong, China, 510060
        • Recrutamento
        • Sun Yat-sen University Cancer Center
        • Contato:
      • Guangzhou, Guangdong, China, 510000
        • Ainda não está recrutando
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • Contato:
    • Guangxi
      • Nanning, Guangxi, China, 530000
        • Ainda não está recrutando
        • Guangxi Zhuang Autonomous Region Cancer Hospital
        • Contato:
          • Rong Liang, Doctor
          • Número de telefone: 18677070811
          • E-mail: 53371159@qq.com
    • Guizhou
      • Zunyi, Guizhou, China, 563000
        • Recrutamento
        • The Affiliated Hospital of Zunyi Medical University
        • Contato:
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150000
        • Ainda não está recrutando
        • Harbin Medical University Cancer Hospital
        • Contato:
        • Contato:
      • Qiqihar, Heilongjiang, China, 161005
        • Ainda não está recrutando
        • Qiqihar First Hospital
        • Contato:
    • Henan
      • Zhengzhou, Henan, China, 450000
        • Ainda não está recrutando
        • Henan Cancer Hospital
        • Contato:
      • Zhengzhou, Henan, China, 450000
        • Ainda não está recrutando
        • The Third People's Hospital of Zhengzhou
        • Contato:
          • HaiCun Wang, Master
          • Número de telefone: 13803833783
          • E-mail: whc1975@126.com
      • Zhengzhou, Henan, China, 450000
        • Ainda não está recrutando
        • The first affiliated hospital of Zhengzhou university
        • Contato:
    • Hubei
      • Jingzhou, Hubei, China, 434099
        • Ainda não está recrutando
        • Jingzhou First People's Hospital
        • Contato:
      • Wuhan, Hubei, China, 430022
        • Ainda não está recrutando
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contato:
    • Hunan
      • Changsha, Hunan, China, 410013
        • Recrutamento
        • Hunan Cancer Hospital
        • Contato:
    • Jiangsu
      • Nanjing, Jiangsu, China, 210008
        • Recrutamento
        • Nanjing Drum Tower Hospital
        • Contato:
      • Nanjing, Jiangsu, China, 210009
        • Recrutamento
        • Zhongda Hospital Southeast University
        • Contato:
      • Nanjing, Jiangsu, China, 210000
        • Ainda não está recrutando
        • Jiangsu Provincial Cancer Hospital
        • Contato:
    • Jiangxi
      • Nanchang, Jiangxi, China, 330000
        • Ainda não está recrutando
        • Jiangxi Provincal People's Hospital
        • Contato:
    • Jilin
      • Changchun, Jilin, China, 130021
        • Ainda não está recrutando
        • Jilin Cancer Hospital
        • Contato:
      • Changchun, Jilin, China, 130021
        • Ainda não está recrutando
        • The first hospital of Jilin University
        • Contato:
    • Liaoning
      • Shenyang, Liaoning, China, 110000
        • Recrutamento
        • Liaoning Cancer Hospital & Institute
        • Contato:
    • Shaanxi
      • Xi'an, Shaanxi, China, 710000
        • Ainda não está recrutando
        • The First Affiliated Hospital of Xi'an Jiaotong University Medical College
        • Contato:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200127
        • Recrutamento
        • Renji Hospital, Shanghai Jiao Tong University School of Medicine
        • Contato:
    • Shanxi
      • Xi’an, Shanxi, China, 710000
        • Ainda não está recrutando
        • The Second Affiliated Hospital of Air Force Medical University
        • Contato:
          • Haichuan Su, Doctor
          • Número de telefone: 18629190366
          • E-mail: cntdgcp@163.com
      • Xi’an, Shanxi, China, 710000
        • Ainda não está recrutando
        • The First Affiliated Hospital of Air Force Medical University
        • Contato:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300202
        • Recrutamento
        • Tianjin Medical University Cancer Institute & Hospital
        • Contato:
          • Zhanyu Pan, Master
          • Número de telefone: 18622221256
          • E-mail: tjpanzy@126.com
      • Tianjin, Tianjin Municipality, China, 300121
        • Ainda não está recrutando
        • Tianjin Union Medical Center
        • Contato:
          • Mingqing Zhang, Doctor
          • Número de telefone: 15122875158
          • E-mail: zmq1003@163.com
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830054
        • Ainda não está recrutando
        • Xinjiang Medical University Affiliated Tumor Hospital
        • Contato:
    • Zhejiang
      • Lishui, Zhejiang, China, 323000
        • Recrutamento
        • Lishui Municipal Central Hospital
        • Contato:
          • Yanru Xie, Master
          • Número de telefone: 13567615770
          • E-mail: 43437677@qq.com

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
  • Age: 18-75 years (including the boundary when signing the informed consent form)
  • Eastern Cooperative Oncology Group (ECOG) score: 0-1
  • Expected survival of more than 3 months
  • Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
  • HER2-Abnormally Expressed tested
  • Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
  • Participants should agree to use contraception during the study and for 6 months after the end

Exclusion Criteria:

  • Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
  • Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
  • Active inflammatory bowel disease within 28 days prior to first dose
  • Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
  • Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
  • Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
  • Had wounds or fractures that had not been healed for a long time
  • Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
  • Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
  • Participants with any severe and/or uncontrolled disease
  • Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
  • Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
  • Failure to control serous effusions requiring repeated drainage
  • Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
  • Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
  • Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
  • Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
  • History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
  • Previous history of severe allergy of unknown origin
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: TQB2930 injection +chemotherapy + Bevacizumab injection

TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis.

Comparador Ativo: TQB2930 injection +chemotherapy

TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Recommended Phase 2 Dose
Prazo: Baseline up to 21 days

It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial.

Baseline up to 21 days
Adverse event (AE)
Prazo: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)

Incidence and severity of adverse events.

From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
Objective Response Rate
Prazo: Baseline up to 24 months

The proportion of participants achieving complete response and partial response among the total evaluable cases.

Baseline up to 24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Half-life
Prazo: Baseline up to 24 months

The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value.

Baseline up to 24 months
Plasma concentration-time profiles
Prazo: Baseline up to 24 months

Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis.

Baseline up to 24 months
Apparent clearance
Prazo: Baseline up to 24 months

The rate at which the drug is cleared from the body.

Baseline up to 24 months
Apparent terminal volume of distribution
Prazo: Baseline up to 24 months

Describe the drug distribution in the body.

Baseline up to 24 months
Trough plasma concentration
Prazo: Baseline up to 24 months

Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing).

Baseline up to 24 months
Disease Control Rate
Prazo: Baseline up to 24 months

The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1.

Baseline up to 24 months
Duration Of Response
Prazo: Baseline up to 24 months

The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause.

Baseline up to 24 months
Progression Free Survival
Prazo: Baseline up to 24 months

Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause.

Baseline up to 24 months
Overall Survival
Prazo: Baseline up to 24 months

The time from the start of initial treatment to death from any cause.

Baseline up to 24 months
Anti-Drug Antibodies (ADA) incidence
Prazo: Baseline up to 24 months

Proportion of anti-drug antibody produced in the population of patients using the drug.

Baseline up to 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de setembro de 2026

Conclusão Primária (Estimado)

1 de junho de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de junho de 2026

Primeira postagem (Real)

17 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever